[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - Other\"Intervention group:\" Patients with Covid 19 who, in addition to the usual treatment regimens, receive a single dose of infliximab (4 mgr/kg) for 2 hours by infusion. The patient will be evaluated for vital signs, oxygen levels, and laboratory parameters at baseline and on the seventh and fourteenth days..", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Placebo\"Control group: \"Patients with Covid 19 receiving common treatment regimens also receive a placebo. The patient will be evaluated for vital signs, oxygen levels, and laboratory parameters at baseline and on the seventh and fourteenth days.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": 650, "treatment_name": "Infliximab", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]